The stock of Ironwood Pharmaceuticals Inc (IRWD) has gone down by -6.28% for the week, with a -13.95% drop in the past month and a -24.82% drop in the past quarter. The volatility ratio for the week is 8.40%, and the volatility levels for the past 30 days are 7.64% for IRWD. The simple moving average for the past 20 days is -13.41% for IRWD’s stock, with a -45.57% simple moving average for the past 200 days.
Is It Worth Investing in Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Right Now?
Additionally, the 36-month beta value for IRWD is 0.41. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 3 rating it as “overweight,” 5 rating it as “hold,” and 1 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for IRWD is 155.77M and currently, short sellers hold a 7.03% ratio of that float. The average trading volume of IRWD on November 26, 2024 was 1.61M shares.
IRWD) stock’s latest price update
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD)’s stock price has soared by 6.59 in relation to previous closing price of 3.35. Nevertheless, the company has seen a loss of -6.28% in its stock price over the last five trading days. businesswire.com reported 2024-11-13 that BOSTON–(BUSINESS WIRE)–Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Operating Officer and Chief Financial Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 7:30 a.m. GT at the Waldorf Hilton in London. A live webcast of Ironwood’s fireside chat will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. A replay of the webcast will be a.
Analysts’ Opinion of IRWD
Many brokerage firms have already submitted their reports for IRWD stocks, with Leerink Partners repeating the rating for IRWD by listing it as a “Market Perform.” The predicted price for IRWD in the upcoming period, according to Leerink Partners is $5 based on the research report published on September 09, 2024 of the current year 2024.
CapitalOne, on the other hand, stated in their research note that they expect to see IRWD reach a price target of $4, previously predicting the price at $12. The rating they have provided for IRWD stocks is “Equal Weight” according to the report published on August 08th, 2024.
Craig Hallum gave a rating of “Buy” to IRWD, setting the target price at $21 in the report published on January 17th of the current year.
IRWD Trading at -14.29% from the 50-Day Moving Average
After a stumble in the market that brought IRWD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.26% of loss for the given period.
Volatility was left at 7.64%, however, over the last 30 days, the volatility rate increased by 8.40%, as shares sank -16.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.09% lower at present.
During the last 5 trading sessions, IRWD fell by -7.22%, which changed the moving average for the period of 200-days by -77.00% in comparison to the 20-day moving average, which settled at $4.12. In addition, Ironwood Pharmaceuticals Inc saw -68.79% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IRWD starting from Davis Andrew, who sale 5,360 shares at the price of $4.08 back on Nov 18 ’24. After this action, Davis Andrew now owns 284,685 shares of Ironwood Pharmaceuticals Inc, valued at $21,869 using the latest closing price.
Emany Sravan Kumar, the SVP, COO and CFO of Ironwood Pharmaceuticals Inc, sale 11,001 shares at $4.08 during a trade that took place back on Nov 18 ’24, which means that Emany Sravan Kumar is holding 309,572 shares at $44,884 based on the most recent closing price.
Stock Fundamentals for IRWD
Current profitability levels for the company are sitting at:
- 0.29 for the present operating margin
- 1.0 for the gross margin
The net margin for Ironwood Pharmaceuticals Inc stands at 0.07. The total capital return value is set at 0.32. Equity return is now at value -559.14, with -0.54 for asset returns.
Based on Ironwood Pharmaceuticals Inc (IRWD), the company’s capital structure generated -2.12 points at debt to capital in total, while cash flow to debt ratio is standing at 0.59. The debt to equity ratio resting at -0.68. The interest coverage ratio of the stock is 3.38.
Currently, EBITDA for the company is -924.86 million with net debt to EBITDA at 1.19. When we switch over and look at the enterprise to sales, we see a ratio of 1.82. The receivables turnover for the company is 4.97for trailing twelve months and the total asset turnover is 0.97. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.62.
Conclusion
In conclusion, Ironwood Pharmaceuticals Inc (IRWD) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
